Mark Frasier earned an undergraduate degree in biochemistry from the University of Dayton, Dayton, Ohio, USA, and a Ph.D. degree in pharmacology from Loyola University Chicago, Chicago, Ill, USA. He completed his postdoctoral work in the Neuroscience Discovery Research Group at Eli Lilly, Inc., in Indianapolis, Ind, USA, where he worked on drug-discovery research in Parkinson's and Alzheimer's diseases. Dr. Frasier has published on the molecular biology of neurodegenerative diseases in addition to the development of biomarkers for Parkinson's and Alzheimer's diseases. As Vice President, Research Programs, Dr. Frasier comanages a team of research professionals who stay closely linked to the Parkinson’s research community in order to develop an aggressive and innovative agenda for accelerating research and drug development for Parkinson’s disease. He regularly meets with academic and industry researchers around the world to identify promising proposals to support, providing troubleshooting, and ongoing management of projects as they go forward. He also supports the Foundation’s priority interest in developing biomarkers for Parkinson’s disease that will accelerate clinical trials of new drugs.
Biography Updated on 6 January 2013